Axsome Therapeutics (AXSM) Return on Capital Employed (2016 - 2026)

Axsome Therapeutics has disclosed Return on Capital Employed across 11 years of filings, most recently posting 17.09% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 17.09%, up 6272.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.09% (up 6272.0% YoY), and the FY2025 annual result was 15.37%, up 6519.0% from the prior year.
• Return on Capital Employed came in at 17.09% for Q1 2026 at Axsome Therapeutics, down from 12.8% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 12.8% in Q4 2025 to a low of 212.43% in Q1 2022.
• The 5-year median for Return on Capital Employed is 75.34% (2022), against an average of 76.5%.
• Across the five-year window, Return on Capital Employed plunged 15140 bps in 2022 and surged 15548 bps in 2023, its largest moves.
• Axsome Therapeutics' Return on Capital Employed stood at 75.34% in 2022, then surged by 32 bps to 50.87% in 2023, then slumped by 65 bps to 83.78% in 2024, then soared by 85 bps to 12.8% in 2025, then plunged by 34 bps to 17.09% in 2026.
• The last three Return on Capital Employed figures came in at 17.09% (Q1 2026), 12.8% (Q4 2025), and 72.2% (Q3 2025), per Business Quant data.